Swiss Wearable Brand MyKronoz Breaks Worldwide Records with its Hybrid Smartwatch ZeTime, on the Sidelines of a Challenging Baselworld 2018
On the sidelines of a downsized Baselworld 2018, MyKronoz, the premier watchmaking brand of the smart generation today announces record-breaking crowdfunding results of its hybrid smartwatch ZeTime, with more than $8,000,000 raised in less than a year. The international success of its unique and groundbreaking flagship wearable is followed by the release of a new digital video campaign “I’m a watch; I’m a smartwatch”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180322005963/en/
MyKronoz ZeTime Petite & Regular top $8M in crowdfunding (Photo: Business Wire)
After a historic 35-days Kickstarter campaign launched in March 2017, ZeTime has pursued, since then, its crowdfunding journey on a variety of international and local platforms: Indiegogo, Makuake in Japan, Zec Zec in Taïwan, Wadiz in Korea and on the leading chinese e-commerce website JD.com. Further to this online momentum, MyKronoz has successfully shipped to over 100 countries close to 40,000 backers, who are proudly wearing their hybrid smartwatch everyday. In addition, ZeTime is now available on Amazon as well as at the most prestigious offline retailers worldwide.
“With ZeTime, we managed to create a new standard: the one and only hybrid wearable device that perfectly reconciles traditional watch lovers and connected devices’ intenders” said Boris Brault, CEO of MyKronoz. He adds: “Our strong electronic background combined with our Swiss DNA gives us a significant advantage over the watch and wearables industries to develop consumer centric and nicely designed products. In a context of uncertainty weighting on the watch market, and although most of the wearable makers are not attending this year Baselworld, I strongly believe we are developing the right strategy. Combining design, features and affordable prices to ensure our company growth and acquire a leadership position.”
The young Swiss challenger to reaffirm its willingness to disrupt a well-established industry, puts the consumer at the center of its product development and innovation strategy while learning from the weaknesses of the traditional watchmakers.
To increase consumer engagement and worldwide brand awareness, MyKronoz just released the fun “I’m a watch; I’m a smartwatch” video series. Debuting this week on social platforms, the 6 episodes portray two rival quirky characters who respectively personify the watch and the smartwatch.
The world's first hybrid smartwatch with mechanical hands over a color touchscreen, ZeTime offers the classic design of a Swiss timepiece with most advanced features of a smartwatch. MyKronoz’s proprietary ‘Smart Movement’ technology enables ZeTime’s always-on hands to function for up to 30 days with a single charge, ensuring the primary function of the watch – to tell time – is always running. With a retail price starting at $199, the hybrid device is available in two different case sizes (39mm and 44mm) and displays (1.05 inch and 1.22-inch). ZeTime boasts three collections comprising a variety of watch case finishing and bands, to appeal to a wide audience.
With $8M raised in crowdfunding, MyKronoz and ZeTime have become the most funded European company in Kickstarter history, most funded hybrid smartwatch and product of 2017.
Founded in January 2013, MyKronoz is a Swiss company headquartered in Geneva that designs and develops wearable devices to expand and facilitate the connected experience of the smart generation. Bringing together the essence of watchmaking tradition with innovative technology, MyKronoz offers a full range of affordable and stylish wearables, starting at a price point of $39 only, spanning across 4 product categories: activity trackers, smartwatches, hybrid smartwatches and watch phones, all compatible with iOS and Android.
Present in more than 40 countries, carried by major retailers and partners worldwide (Orange, Auchan, Carrefour, Amazon, Best Buy...), MyKronoz has sold more than 3 million products and established itself as a fierce challenger to both tech and traditional watchmakers.
MyKronoz is part of BOW Group, a global player in the Internet of Things (IoT), operating worldwide in the wearables, connected vehicles and smart home markets. In July 2015, BOW raised €10 million from NextStage AM in series A funding round and closed in November 2017 its $23.5 million series B funding lead by PM Equity Partner, the corporate venture fund of Philip Morris International.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Brightree Acquires Mobile Delivery Provider Apacheta to Streamline HME Delivery17.12.2018 14:05 | Pressemelding
Brightree, a leading provider of cloud-based software helping out-of-hospital providers improve business performance and patient outcomes, today announced it has acquired privately held mobile delivery and cloud-based software-as-a-service (SaaS) provider Apacheta Corporation, further expanding the SaaS portfolio of Brightree’s owner, ResMed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005121/en/ The terms of the transaction were not disclosed. Apacheta offers mobile applications that empower companies to automate and streamline business processes in route sales, field marketing, pick-up and delivery, transportation and field services. Apacheta and its Media, PA-based employees will join Brightree, whose platform it has been integrated with since 2015. A secure mobile delivery module for ordering and tracking medical equipment was the number one feature request of HMEs in a recent customer satisfaction survey. Brigh
Transphorm’s High Voltage GaN FETs Amp Up Marotta Controls’ Military Grade High Frequency Power Supply17.12.2018 14:00 | Pressemelding
Transphorm Inc.—the leader in the design and manufacturing of the highest reliability and first JEDEC- and AEC-Q101 qualified gallium nitride (GaN) semiconductors—today announced with Marotta Controls that the Aerospace and Defense supplier’s upcoming power supply unit (PSU) replaces incumbent Silicon (Si) MOSFETs with high voltage GaN PQFN devices to offer advanced benefits. Marotta’s latest design operates at high frequency in a conduction-cooled mechanically constrained envelope. The supply’s topology features hard switching and an automatic transformer RESET capability where transistor voltage stresses are clamped to the input voltage. The GaN devices increase the PSU’s efficiency dramatically and alleviate a complex thermal design in the small form factor package. “The demand on our power supplies and expectation of performance is high,” explained Mike Scruggs, Principal Engineer, Marotta Controls. “This particular complex PSU needed to reliably convert and distribute power in a s
New Phase 3 data demonstrate superiority of TREMFYA®▼ (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 4817.12.2018 12:56 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the ECLIPSE study demonstrating that TREMFYA® (guselkumab) was superior to Cosentyx® (secukinumab)* in treating adults with moderate to severe plaque psoriasis for the primary endpoint assessed at week 48. Data from the multicentre, randomised, double-blind head-to-head Phase 3 study demonstrated that 84.5 percent of patients treated with guselkumab achieved at least 90 percent improvement in their baseline Psoriasis Area Severity Index (PASI) score at week 48, compared with 70.0 percent of patients treated with secukinumab (p<0.001).1 These data, presented at the 3rd Inflammatory Skin Disease Summit (ISDS) in Vienna, 12–15 December, mark the first-ever results from a head-to-head study comparing an interleukin (IL)-23-targeted biologic therapy (guselkumab) with an IL-17 inhibitor (secukinumab). ECLIPSE is Janssen’s fourth Phase 3 study for guselkumab in plaque psoriasis2-4 and is part of a comprehen
Celgene Corporation Announces Celgene Cancer Care Links™ Program Grant Recipients17.12.2018 12:30 | Pressemelding
Celgene Corporation (NASDAQ:CELG) today announced ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support cancer healthcare capacity building in resource-constrained countries around the world. The programs selected are expected to support established institutions partnering with in-country medical centers that provide essential cancer care services including awareness and education, prevention, diagnosis and care. The Celgene Cancer Care Links program is an initiative of Celgene Global Health, which focuses on healthcare challenges facing patients in developing parts of the world. “Celgene Cancer Care Links is another program we have created to make a meaningful impact for patients and healthcare systems around the world,” said Mark J. Alles, Chairman and Chief Executive Officer of Celgene. “We are excited to announce the first round of grants through this initiative and wish these world-renowned organizations and institutions
Ras Al Khaimah Marks New Year’s Eve with Amazing Fireworks and New Guinness World Record Bid17.12.2018 11:14 | Pressemelding
This New Year’s Eve, Ras Al Khaimah is the place to be as the Emirate readies to host the most spectacular celebration with a 12-minute fireworks display - the bid for a new Guinness World Record display - and an array of family-oriented activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005309/en/ Marjan, Ras Al Khaimah’s master-developer of freehold projects, will manage the show to mark 2019 with a glittering array of activities that will entertain all at its flagship development, Al Marjan Island. With three additional viewing areas around Al Marjan Island, New Year’s Eve in Ras Al Khaimah has fun and thrills in store for local and international visitors. Abdulla Al Abdouli, Managing Director & CEO of Marjan, said: “This year, we are offering exciting family activities that will delight all in the run-up to the amazing fireworks display that aims to set a new Guinness World Record. The event will position t
Mobidiag Announces Joint Venture with Autobio Diagnostics and €10m Equity Investment17.12.2018 09:52 | Pressemelding
Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, today announces that it has entered into a joint venture (‘JV’) agreement with Autobio Diagnostics (‘Autobio’), one of the leading clinical diagnostics companies in China, to commercialise the Novodiag® platform in China. In addition, Mobidiag announces that it has secured a separate €10m equity investment from Autobio. Lynx Financial (HK) Ltd, served as the exclusive financial advisor to Mobidiag in this transaction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005272/en/ Mobidiag and Autobio will jointly invest €12.3m to establish a joint venture company in China. Autobio will invest €8m in cash to hold 65%, and Mobidiag will invest €4.3m to hold 35%. Mobidiag will grant to the JV an exclusive license for human infectious disease assays (except for sepsis) for China. Initial activities of the JV will i